We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Outwitting Cancer's Defense Mechanism

By Biotechdaily staff writers
Posted on 13 Sep 2002
A study has found that tumor cells inoculated with the adenoviral E1A oncogene become sensitive to tumor necrosis factor (TNF)- mediated immune system attack. More...
The study was published in the July 23, 2002, issue of the Proceedings of the National Academy of Sciences.

Investigators from the University of Illinois at Chicago (UIC, USA) looked at the sequence of molecular events that occur when cancer cells are exposed to TNF. This experiment was designed to mimic the immune system's response to tumor growth. Normally, cancer cells are not susceptible to TNF-mediated destruction. However, when the E1A gene was inserted into the malignant cells, the tumor cells were no longer able to defend themselves.

"Multiple molecular mechanisms triggered by E1A prevent tumor cells from thwarting an immunological attack,” explained first author Dr. James Cook, chief of infectious diseases at UIC. "Further definition of these mechanisms will help us develop new concepts that may be useful for treating cancer, in part by enlisting the body to become a more active partner in fighting the disease.”



Related Links:
University of Illinois at Chicago

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
POC Immunoassay Analyzer
Procise DX
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.